Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Gevokizumab> ?p ?o. }
Showing items 1 to 56 of
56
with 100 items per page.
- Gevokizumab abstract "Gevokizumab is a potent monoclonal antibody, developed by XOMA Corporation, with unique allosteric modulating properties and the potential to treat patients with a wide variety of inflammatory and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and modulates the cellular signaling events that produce inflammation. IL-1 beta has been shown to be involved in diverse array of disease states, including non-infectious uveitis (including Behçet's uveitis), cardiovascular disease, and other auto-inflammatory diseases. Gevokizumab currently is being studied in a global Phase 3 clinical program, termed EYEGUARD™, which is being conducted by SERVIER and XOMA. This program is designed to determine gevokizumab's ability to treat acute non-anterior non-infectious uveitis (NIU) in EYEGUARD-A, to prevent disease flares in patients with Behçet's uveitis in EYEGUARD-B, and to prevent disease flares in NIU patients who are controlled with steroids and immunosuppressants in EYEGUARD-C. XOMA has a Proof-of-Concept (POC) program underway in which the Company is exploring the efficacy and safety of gevokizumab in multiple indications. The Company reported promising data in January 2013 from the interim analysis of a Phase 2 study in moderate to severe inflammatory acne. Data from the National Eye Institute's study of gevokizumab in patients with active non-infectious anterior scleritis is expected in 2014. XOMA anticipates full results from its two POC studies in patients with erosive osteoarthritis of the hand in the first quarter of 2014. Separately, SERVIER initiated a Phase 2 study to determine gevokizumab's ability to reduce arterial wall inflammation in patients with marked atherosclerotic plaque inflammation and who have experienced an acute coronary syndrome in the previous twelve months, as well as POC studies in polymyositis/dermatomyositis, giant cell arteritis, and Schnitzler syndrome. Information about gevokizumab clinical studies can be found at www.clinicaltrials.gov and www.clinicaltrialsregister.eu.".
- Gevokizumab atcPrefix "none".
- Gevokizumab casNumber "1129435-60-4".
- Gevokizumab fdaUniiCode "QX3JU54GYQ".
- Gevokizumab wikiPageExternalLink www.eyeguard.com.
- Gevokizumab wikiPageID "33024037".
- Gevokizumab wikiPageRevisionID "600575604".
- Gevokizumab atcPrefix "none".
- Gevokizumab c "6442".
- Gevokizumab casNumber "1129435".
- Gevokizumab chemspiderid "NA".
- Gevokizumab h "9962".
- Gevokizumab hasPhotoCollection Gevokizumab.
- Gevokizumab mabType "mab".
- Gevokizumab molecularWeight "145.2".
- Gevokizumab n "1710".
- Gevokizumab o "2010".
- Gevokizumab s "52".
- Gevokizumab source "zu/o".
- Gevokizumab target Interleukin_1-beta.
- Gevokizumab type "mab".
- Gevokizumab unii "QX3JU54GYQ".
- Gevokizumab verifiedfields "changed".
- Gevokizumab verifiedrevid "458274816".
- Gevokizumab subject Category:Monoclonal_antibodies.
- Gevokizumab type Abstraction100002137.
- Gevokizumab type Antibody115027189.
- Gevokizumab type Chemical114806838.
- Gevokizumab type Compound114818238.
- Gevokizumab type Macromolecule114944888.
- Gevokizumab type Material114580897.
- Gevokizumab type Matter100020827.
- Gevokizumab type Molecule114682133.
- Gevokizumab type MonoclonalAntibodies.
- Gevokizumab type MonoclonalAntibody115029781.
- Gevokizumab type OrganicCompound114727670.
- Gevokizumab type Part113809207.
- Gevokizumab type PhysicalEntity100001930.
- Gevokizumab type Protein114728724.
- Gevokizumab type Relation100031921.
- Gevokizumab type Substance100019613.
- Gevokizumab type Thing100002452.
- Gevokizumab type Unit109465459.
- Gevokizumab type Drug.
- Gevokizumab type FunctionalSubstance.
- Gevokizumab comment "Gevokizumab is a potent monoclonal antibody, developed by XOMA Corporation, with unique allosteric modulating properties and the potential to treat patients with a wide variety of inflammatory and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and modulates the cellular signaling events that produce inflammation.".
- Gevokizumab label "Gevokizumab".
- Gevokizumab label "Gevokizumab".
- Gevokizumab label "جيفوكيزوماب".
- Gevokizumab sameAs Gevokizumab.
- Gevokizumab sameAs m.0h51jmt.
- Gevokizumab sameAs Q5554924.
- Gevokizumab sameAs Q5554924.
- Gevokizumab sameAs Gevokizumab.
- Gevokizumab wasDerivedFrom Gevokizumab?oldid=600575604.
- Gevokizumab isPrimaryTopicOf Gevokizumab.